Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

eXoZymes Inc. - Common Stock (NQ:EXOZ)

7.350 +0.050 (+0.68%)
Streaming Delayed Price Updated: 10:22 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about eXoZymes Inc. - Common Stock

< Previous 1 2 Next >
News headline image
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
Via ACCESS Newswire
News headline image
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
Via ACCESS Newswire
News headline image
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
Via ACCESS Newswire
News headline image
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
Via ACCESS Newswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
Via ACCESS Newswire
News headline image
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
Via ACCESS Newswire
News headline image
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
Via ACCESS Newswire
News headline image
CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference
Via ACCESS Newswire
News headline image
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
Via ACCESS Newswire
News headline image
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
Via ACCESS Newswire
News headline image
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
Via ACCESS Newswire
News headline image
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
Via ACCESS Newswire
News headline image
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
Via ACCESS Newswire
News headline image
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
Via ACCESS Newswire
News headline image
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
Via ACCESS Newswire
News headline image
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health
Via ACCESS Newswire
News headline image
Bringing clarity and precision to the cell-free space by introducing exozymes
From eXoZymes Inc.
Via GlobeNewswire
News headline image
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), and ARRIVE AI
Via ACCESS Newswire
News headline image
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
From eXoZymes Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.